NCT07549698
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Recruiting
PHASE1Ages 18+InterventionalTreatmentCRISPR Therapeutics AG
~60 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:CTX112
At a glance
Recruiting sites
6 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.
Measured over From CTX112 infusion up to 28 days post infusion.
Conditions
Where it's being run
10 sites across 4 statesGermany4
Spain4
Minnesota1
Nebraska1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.From CTX112 infusion up to 28 days post infusion.
Incidence of dose-limiting toxicities.